Neuren Pharmaceuticals Limited (NURPF)

Neuren Pharmaceuticals Limited (NURPF) — VMCI valuation read

Across 120 indicators, Neuren Pharmaceuticals Limited (NURPF) lands at VMCI 55/100. The Healthcare sector median is 50, so the 5-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on NURPF in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, NURPF trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 3.5x is the binding constraint on the bear case for NURPF on the trailing balance sheet.

NURPF fell 1.4% over the trailing 7 days, with a -10.4% read on a 30-day basis.